The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...

Sarepta stock crashed Friday — wiping out all of its restructuring-tied gains — after a third recipient of one of its gene therapies died.

(Reuters) -Shares of Sarepta Therapeutics declined 17% in early trading on Friday after a patient who had received one of the company's experimental gene therapies died, deepening investor concern ...

According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...